The role of glucagon on type 2 diabetes at a glance

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Godoy Matos, Amélio F ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

GLP 1; Hiperglucagonemia; Incretin effect; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; PRAMLINTIDE;

ANTIDIABETIC ACTIVITY; DISEASE COURSE; DRUG EFFICACY; GLUCAGON RELEASE; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; REVIEW;

EID: 84906927474     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-91     Document Type: Review

References (44)

1. Aqueous extracts of the pancreas. 1. Influence on the carbohydrate metabolism of depancreatized animals. Murlin JR, Clough HD, Gibbs CBF, Stokes AM, J Biol Chem 1923 56 253 296
2. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. Sutherland EW, De Duve C, J Biol Chem 1948 175 663 674
3. Glucagon antibodies and their use for immunoassay for glucagon. Unger RH, Eisentraut AM, Mc CM, Keller S, Lanz HC, Madison LL, Proc Soc Exp Biol Med 1959 102 621 623
4. Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P, Diabetes Obes Metab 2011 13 Suppl 1 95 105
5. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Gromada J, Franklin I, Wollheim CB, Endocr Rev 2007 28 84 116
6. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB, Diabetes 2005 54 1808 1815
7. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q, Cell Metab 2006 3 47 58
8. Insulin as a physiological modulator of glucagon secretion. Bansal P, Wang Q, Am J Physiol Endocrinol Metab 2008 295 751 E761
9. Brain control of insulin and glucagon secretion. Osundiji MA, Evans ML, Endocrinol Metab Clin North Am 2013 42 1 14
10. Inhibitory effects of leptin on pancreatic alpha-cell function. Tuduri E, Marroqui L, Soriano S, Ropero AB, Batista TM, Piquer S, Lopez-Boado MA, Carneiro EM, Gomis R, Nadal A, Quesada I, Diabetes 2009 58 1616 1624
11. Dose-response for glucagonostatic effect of amylin in rats. Gedulin BR, Rink TJ, Young AA, Metabolism 1997 46 67 70
12. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ, Gastroenterology 2007 132 2131 2157
13. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Heller RS, Aponte GW, Am J Physiol 1995 269 852 G860
14. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F, Diabetologia 2012 55 3262 3272
15. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS, J Histochem Cytochem 2008 56 841 851
16. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F, Diabetes 1996 45 257 261
17. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Heller RS, Kieffer TJ, Habener JF, Diabetes 1997 46 785 791
18. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S, Habib AM, Moritoh Y, Zang E, Reimann F, Rosengren AH, Shibasaki T, Gribble F, Renström E, Seino S, Eliasson L, Rorsman P, Cell Metab 2010 11 543 553
19. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. de Heer J, Rasmussen C, Coy DH, Holst JJ, Diabetologia 2008 51 2263 2270
20. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Muoio DM, Newgard CB, Nat Rev Mol Cell Biol 2008 9 193 205
21. Induction of apoptosis of Beta cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus. Lim M, Park L, Shin G, Hong H, Kang I, Park Y, Ann N Y Acad Sci 2008 1150 311 315
22. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Nauck M, Stockmann F, Ebert R, Creutzfeldt W, Diabetologia 1986 29 46 52
23. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W, J Clin Endocrinol Metab 1986 63 492 498
24. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Meier JJ, Nauck MA, Diabetes 2010 59 1117 1125
25. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsboll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ, J Clin Endocrinol Metab 2003 88 4897 4903
26. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes. An Z, Prigeon RL, D'Alessio DA, J Clin Endocrinol Metab 2013 98 4702 4708
27. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S, Diabetes Care 2011 34 Suppl 2 251 S257
28. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK, J Clin Endocrinol Metab 2010 95 3309 3317
29. Studies of pancreatic alpha cell function in normal and diabetic subjects. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM, J Clin Invest 1970 49 837 848
30. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, Holst JJ, Meier JJ, Diabetes 2011 60 2160 2168
31. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Borghi VC, Wajchenberg BL, Cesar FP, Metabolism 1984 33 1068 1074
32. Relationship between insulin S, cardiovascular disease risk project I: association of fasting glucagon and proinsulin concentrations with insulin resistance. Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, Flyvbjerg A, Golay A, Hojlund K, Diabetologia 2007 50 2342 2347
33. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, Herrera PL, Polonsky KS, McGuinness OP, Kulkarni RN, Cell Metab 2009 9 350 361
34. Paracrinology of islets and the paracrinopathy of diabetes. Unger RH, Orci L, Proc Natl Acad Sci U S A 2010 107 16009 16012
35. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK, Am J Physiol Endocrinol Metab 2011 300 1038 E1046
36. beta-cell dedifferentiation and type 2 diabetes. Dor Y, Glaser B, N Engl J Med 2013 368 572 573
37. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Unger RH, Cherrington AD, J Clin Invest 2012 122 4 12
38. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH, Diabetes 2011 60 391 397
39. Fibroblast growth factor 21 (FGF21) and glucagon like-peptide 1 contribute to diabetes resistance in glucagon receptor deficient mice. Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B, Diabetes 2014 63 101 110
40. Taking aim at islet hormones with GLP-1: is insulin or glucagon the better target? D'Alessio DA, Diabetes 2010 59 1572 1574
41. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ, Diabetes 2010 59 1765 1770
42. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A, J Clin Endocrinol Metab 2004 89 2078 2084
43. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O, Diabetes 2004 53 1187 1194
44. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Kielgast U, Krarup T, Holst JJ, Madsbad S, Diabetes Care 2011 34 1463 1468